Payment overview · 2025
General Payments
$139.01
11 reported records · 5 companies
Healthcare provider profile · identity verified
John Timothy Dow, MD
Allopathic & Osteopathic Physicians|Family Medicine · TRUMANN, AR · NPI 1386605491
Verified facts
What the public records show
CMS Open Payments records show John Timothy Dow, MD received $139.01 in general payments during 2025 across 11 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.29 | 34.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.10 | 21.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.20 | 18.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.69 | 15.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.73 | 10.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $139.01 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $47.29 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.10 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.69 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 109 |
| Gabapentin | Gabapentin | 262 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 60 |
| Lisinopril | Lisinopril | 228 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 45 |
| Alprazolam | Alprazolam | 204 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 37 |
| Omeprazole | Omeprazole | 179 | 41 |
| Potassium Chloride | Potassium Chloride | 175 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 168 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 40 |
| Furosemide | Furosemide | 148 | 40 |
| Losartan Potassium | Losartan Potassium | 148 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 24 |
| Metformin Hcl | Metformin Hcl | 135 | 36 |
| Spironolactone | Spironolactone | 133 | 28 |
| Clonazepam | Clonazepam | 127 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 20 |
| Carvedilol | Carvedilol | 116 | 27 |
| Eliquis | Apixaban | 115 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 28 |
| Ezetimibe | Ezetimibe | 114 | 29 |
| Famotidine | Famotidine | 110 | 22 |
| Jardiance | Empagliflozin | 108 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 22 |
| Tramadol Hcl | Tramadol Hcl | 101 | 28 |
| Celecoxib | Celecoxib | 92 | 24 |
| Trazodone Hcl | Trazodone Hcl | 86 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 24 |
| Simvastatin | Simvastatin | 78 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 15 |
| Allopurinol | Allopurinol | 76 | 16 |
| Mirtazapine | Mirtazapine | 75 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 20 |
| Donepezil Hcl | Donepezil Hcl | 67 | 16 |
| Indapamide | Indapamide | 66 | 18 |
| Diazepam | Diazepam | 65 | 11 |
| Glipizide | Glipizide | 64 | 13 |
| Farxiga | Dapagliflozin Propanediol | 63 | 18 |
| Nitroglycerin | Nitroglycerin | 63 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 15 |
| Buspirone Hcl | Buspirone Hcl | 60 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 13 |
| Montelukast Sodium | Montelukast Sodium | 59 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 14 |
| Meloxicam | Meloxicam | 57 | 18 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 57 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 20 |
| Pregabalin | Pregabalin | 53 | 12 |
| Cephalexin | Cephalexin | 50 | 35 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Linzess | Linaclotide | 46 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 22 |
| Meclizine Hcl | Meclizine Hcl | 43 | suppressed |
| Prednisone | Prednisone | 42 | 33 |
| Ondansetron Odt | Ondansetron | 40 | 14 |
| Memantine Hcl | Memantine Hcl | 39 | 11 |
| Ozempic | Semaglutide | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Bumetanide | Bumetanide | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 25 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 22 |
| Atenolol | Atenolol | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 19 |
| Lactulose | Lactulose | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Constulose | Lactulose | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Zonisamide | Zonisamide | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $139.01 · 11 records | Otsuka America Pharmaceutical, Inc. | BREZTRI, OTEZLA, REPATHA, REXULTI, VOQUEZNA, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error